Similarly, the DELIVER trial demonstrated that the SGLT2 inhibitor dapagliflozin reduced the risk of worsening HF or cardiovascular death in HFpEF and HF with mid‐range ejection fraction (HFmrEF) patients.3 This evidence concerns the gene SLC5A2 and hydrops fetalis.